Charlotte Robinson

DocwireNews

Drug maker Novo Nordisk faces an impairment loss of $818.9 million in the second quarter of 2024 after calling off a phase 3 drug trial. CLARION-CKD was investigating the mineralocorticoid receptor antagonist ocedurenone for treatment of uncontrolled hypertension and advanced chronic kidney disease.Novo Nordisk acquired ocedurenone from KBP Biosciences&nbsp;in October 2023 in a deal worth as much as $1.3 billion. The drug had previously undergone nine studies and met its primary end point of a statistically significant improvement in systolic blood pressure in a phase 2b trial. Yet in an interim analysis of the phase 3 trial, ocedurenone failed to meet its primary end point of a reduction in systolic blood pressure from baseline to week 12.The impairment loss is expected to have a negative impact of about 6% on operating growth profit in 2024. Novo Nordisk is determining whether to pursue further development of ocedurenone for other indications.

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

Novo Nordisk Ends CLARION-CKD Trial of Ocedurenone

Chronic Kidney Disease

Novo Nordisk stopped the phase 3 CLARION-CKD trial of ocedurenone for hypertension and advanced chronic kidney disease (CKD) due to disappointing results.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe